Search clinical trials for: alemtuzumab (Campath IH)

Total 660 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Effectiveness and Implementation of mPATH-CRC

Cancer | Colorectal Cancer | Colon Cancer | Rectum Cancer

United States
Radboud University Medical Center

Withdrawn

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (CRUSADE-1)

HCV

Netherlands, Germany
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Royal Marsden NHS Foundation Trust

Completed

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Chronic Lymphocytic Leukaemia
Complejo Hospitalario Universitario de Albacete
University of Warwick; University Hospitals Coventry and Warwickshire NHS Trust and other collaborators

Not yet recruiting

An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Dementia (CAREPATH)

Behavioral Symptoms | Coronary Artery Disease | Heart Failure | Stroke | Hypertension | Diabetes | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Malnutrition | Asthma | Dementia | Alzheimer Disease | Frailty | Sarcopenia | Comorbidities and Coexisting Conditions

Spain
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)

Active, not recruiting

Tolerance by Engaging Antigen During Cellular Homeostasis (TEACH)

Kidney Transplantation | Renal Transplantation | Renal Transplant Recipient

United States
Johns Hopkins University
National Institute on Aging (NIA)

Recruiting

mPATH for Low-income Older Adults

Insomnia | Sedentary Time | Cognitive Decline

United States
Ferring Pharmaceuticals

Completed

A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur® (AME)

Infertility

France
Northwestern University

Terminated

Hematopoietic Stem Cell Support in Vasculitis

Vasculitis

United States
National Cancer Institute (NCI)

Completed

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Multiple Myeloma | Hodgkin's Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Non-Hodgkin's Disease

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Leukemia

United States
Clinical Research Center, Intercard Sp. z o.o.
Corindus, Inc. dba Siemens Healthineers Endovascular Robotics; KCRI Sp. z o.o.

Recruiting

Multicenter Registry on Robotically Assisted PCI - TESLA (TESLA)

Coronary Artery Disease

Poland
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Leukemia, Myelocytic, Acute | Infusions, Intravenous
Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
University of California, San Diego
Pfizer; Celgene Corporation

Completed

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Corindus Inc.

Completed

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions (PRECISION)

Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive Diseases

United States, Israel
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Immunodeficiency Syndrome | Non-Cancer Diagnosis

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Sickle Cell Disease

United States
Washington University School of Medicine

Terminated

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Sickle Cell Disease

United States
Northwestern University

Terminated

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Rheumatoid Arthritis

United States
University of Florida
National Heart, Lung, and Blood Institute (NHLBI)

Completed

QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia

Ischemic Heart Disease

United States
Digital Health Navigation Solutions, Inc
National Cancer Institute (NCI); Wake Forest University Health Sciences

Not yet recruiting

Feasibility of a Colorectal Cancer Screening Web App in Primary Care Patients

Colorectal Cancer Screening

United States
Thermo Fisher Scientific, Inc

Completed

Butterfly - Clinical Performance Study

Coronavirus Infections | COVID-19

United States
Corindus Inc.

Terminated

The ROB-OSTIAL Study

Coronary Artery Disease

Italy
Corindus Inc.

Terminated

Cardiac Cath Lab Staff Radiation Exposure (SAFE-T)

Coronary Artery Disease | Percutaneous Coronary Intervention | Chronic Total Occlusion of Coronary Artery

United States
St. Jude Children's Research Hospital

Completed

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Hodgkin Lymphoma | Myelodysplastic Syndrome (MDS) | Leukemia, Acute Lymphocytic (ALL) | Juvenile Myelomonocytic Leukemia (JMML) | Leukemia, Myeloid, Acute(AML) | Leukemia, Myeloid, Chronic(CML) | Hemoglobinuria, Paroxysmal Nocturnal (PNH) | Lymphoma, Non-Hodgkin (NHL)

United States
Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
Dana-Farber Cancer Institute
Genzyme, a Sanofi Company

Completed

Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Chronic Lymphocytic Leukemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Acute Myeloid Leukemia

United States
Weill Medical College of Cornell University

Completed

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Pirogov Russian National Research Medical University
Russian Academy of Medical Sciences

Unknown

Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection

End-Stage Renal Disease | Kidney Failure

Russian Federation
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Leukemia, Myelocytic, Acute
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection (MINMON)

Liver Diseases | Hepatitis C | HIV-1-infection

United States, Uganda, Brazil, Puerto Rico, South Africa, Thailand
Corindus Inc.

Completed

GRX With ReMOTE: First in Human in India

Percutaneous Coronary Intervention

India
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI); University of North Carolina, Chapel Hill

Active, not recruiting

Digital Outreach Intervention for Lung Cancer Screening (mPATH-Lung)

Lung Cancer

United States
Tehran University of Medical Sciences

Completed

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

Leukemia, Myeloid, Acute | Leukemia, Lymphoblastic, Acute

Iran, Islamic Republic of
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Approved for marketing

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
Paul Szabolcs

Recruiting

Autologous Stem Cell Transplantation for Crohn's Disease

Crohn's Disease

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
Grupo Cooperativo de Estudio y Tratamiento de las...

Completed

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Novo Acute Myeloid Leukemia

Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States, Puerto Rico

Search clinical trials for: alemtuzumab (Campath IH)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations